Premium
Trimethoprim–sulfamethoxazole‐induced rhabdomyolysis in an allogeneic stem cell transplant patient
Author(s) -
Kiel P.J.,
Dickmeyer N.,
Schwartz J.E.
Publication year - 2010
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/j.1399-3062.2010.00524.x
Subject(s) - rhabdomyolysis , medicine , trimethoprim , sulfamethoxazole , complication , creatine kinase , stem cell , immunology , gastroenterology , antibiotics , microbiology and biotechnology , genetics , biology
P.J. Kiel, N. Dickmeyer, J.E. Schwartz. Trimethoprim–sulfamethoxazole‐induced rhabdomyolysis in an allogeneic stem cell transplant patient.
Transpl Infect Dis 2010: 12: 451–454. All rights reserved Abstract: Rhabdomyolysis is a serious, potentially life‐threatening complication diagnosed when creatine phosphokinase levels exceed 1000 U/L. Although many drugs are associated with rhabdomyolysis, the previous reports of trimethoprim–sulfamethoxazole (TMP/SMX)‐induced rhabdomyolysis have involved patients with human immunodeficiency virus/acquired immunodeficiency syndrome. This is the first report, to our knowledge, of TMP/SMX‐induced rhabdomyolysis in an allogeneic stem cell transplant patient.